The known fusion CCDC170-ESR1 was found in three breast cancer samples (Supplementary Fig. S7e) while the well-described promoter substitution event, TMPRSS2-ERG (Supplementary Fig. S7f), was identified in one prostate cancer cell line. Here, ERG is linked to breast carcinoma.